Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer.
Ditzel
Henrik J
HJ
University of Southern Denmark, Odense, Denmark. hditzel@health.sdu.dk
Lyng
Maria B
MB
D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D003131:Combined Modality Therapy; D005260:Female; D020869:Gene Expression Profiling; D005819:Genetic Markers; D006801:Humans; D009364:Neoplasm Recurrence, Local; D011237:Predictive Value of Tests; D011379:Prognosis; D011960:Receptors, Estrogen / Q000187:drug effects / Q000235:genetics*; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology* / Q000627:therapeutic use; D013629:Tamoxifen / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome
D005819:Genetic Markers; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen